Table of contents  by unknown
1309 Bridging to transplant with the HeartMate left ventricular assist device: The
Columbia Presbyterian 12-year experience
Jeffrey A. Morgan, MD, Ranjit John, MD, Vivek Rao, MD, PhD, Alan D. Weinberg, MS,
Brian J. Lee, BS, Pamela A. Mazzeo, BA, Margaret R. Flannery, ANP, Jonathan M. Chen, MD,
Mehmet C. Oz, MD, and Yoshifumi Naka, MD, PhD, New York, NY, and Toronto, Ontario,
Canada
LVADs have become increasingly more effective in bridging patients to transplantation. We
present our 12-year experience with 3 HeartMate devices. Overall bridging success increased
from 63.5% in patients with pneumatic devices to 72.4% in patients with SLVE devices, while
1-, 3-, and 5-year posttransplant actuarial survival increased from 87.5%, 78.1%, and 71.9% in
pneumatics to 91.5%, 86.9%, and 81.3%, respectively, in patients with SLVE devices.
1317 The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of
neointimal and medial thickening in porcine saphenous vein–carotid artery
interposition grafts
Song Wan, FRCS, Anthony P. C. Yim, FRCS, Jason L. Johnson, MSc, Nilima Shukla, PhD,
Gianni D. Angelini, FRCS, Frank C. T. Smith, FRCS, Michael R. Dashwood, PhD, and
Jamie Y. Jeremy, PhD, Hong Kong, China, and Bristol and London, United Kingdom
The administration of an endothelin 1A (ETA) receptor antagonist (BSF 302146) to pigs reduces
saphenous vein graft thickening and promotes positive remodeling through an ETA-mediated
effect on vascular smooth muscle cell replication. The administration of this ETA receptor
antagonist might therefore be therapeutically useful in preventing late vein graft failure in
patients undergoing CABG.
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1323 Lung cancer resection combined with lung volume reduction in patients with
severe emphysema
Cliff K. Choong, FRACS, Bryan F. Meyers, MD, Richard J. Battafarano, MD, PhD,
Tracey J. Guthrie, BSN, Gail E. Davis, MSN, G. Alexander Patterson, MD, and
Joel D. Cooper, MD, St Louis, Mo
Well-selected patients with clinically early-stage lung cancer and severe respiratory limitation
due to emphysema may have a suitable operative risk by undergoing a combined cancer
resection and lung volume reduction surgery. This study reviews our experience with 21 such
patients between 1994 and 2001.
1332 Expression profiling of non–small cell lung carcinoma identifies metastatic
genotypes based on lymph node tumor burden
Chuong D. Hoang, MD, Jonathan D’Cunha, MD, PhD, Sherif H. Tawfic, MD, PhD,
Angelika C. Gruessner, PhD, Robert A. Kratzke, MD, and Michael A. Maddaus, MD,
Minneapolis, Minn
We performed microarray gene expression profiling on laser capture microdissected non–small
cell lung carcinoma cells differentiated on the basis of graded lymph node metastatic cell
burden. This process may identify genotypes associated with metastatic potential.
Table of Contents (continued)
(continued on page 14A)
12A The Journal of Thoracic and Cardiovascular Surgery ● May 2004
ED
ITO
RIA
L
CSP
G
TS
A
CD
ET
CH
D
TX
